The reduced incidence of breast cancer with 5-year prophylaxis with the aromatase inhibitor anastrozole among women at high risk of the disease persists even after anastrozole cessation, suggests long-term results of the IBIS-II* trial presented at SABCS 2019.
The addition of tucatinib to a trastuzumab-capecitabine regimen improved progression-free survival (PFS) in patients with HER2+ metastatic breast cancer (MBC) previously treated with multiple HER2-targeted agents, according to the HER2CLIMB* study presented at SABCS** 2019. Additionally, this improved PFS was also noted in patients with brain metastases.
Younger women with breast cancer who had a mastectomy demonstrated a worse quality of life (QoL) compared with those who underwent breast-conserving surgery (BCS), according to a study presented at SABCS 2018.
Use of a scalp cooling device is effective in reducing alopecia or hair loss in patients with breast cancer who are undergoing neoadjuvant/adjuvant chemotherapy including anthracyclines* and taxanes**, according to studies presented at SABCS 2018.
Women diagnosed with nonmetastatic breast cancer who were adherent to cardiovascular disease (CVD) medications pre-diagnosis had a high risk of becoming nonadherent post-cancer treatment, with nonadherence increasing their risk of CV events, according to a poster presented at the recent San Antonio Breast Cancer Symposium (SABCS 2018).
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.
A structured cardiovascular (CV) exercise programme during adjuvant breast cancer treatment provides significant protection against decline in CV function related to chemotherapy-induced cardiotoxicity, according to the EBBA*-II trial presented at SABCS 2018, indicating that physical activity during treatment for breast cancer can benefit patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng,
10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
A single infusion of the monoclonal antibody rituximab temporarily delays the clinical onset of rheumatoid arthritis (RA) through B-cell depletion, underpinning the preventive potential of rituximab in RA development especially in high-risk individuals, according to the PRAIRI* study.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).